Literature DB >> 32376320

Severe acute respiratory syndrome coronavirus 2 detection in the female lower genital tract.

Pengfei Cui1, Zhe Chen1, Tian Wang1, Jun Dai1, Jinjin Zhang1, Ting Ding1, Jingjing Jiang1, Jia Liu1, Cong Zhang1, Wanying Shan1, Sheng Wang1, Yueguang Rong2, Jiang Chang3, Xiaoping Miao3, Xiangyi Ma4, Shixuan Wang5.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32376320      PMCID: PMC7196539          DOI: 10.1016/j.ajog.2020.04.038

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   10.693


× No keyword cloud information.
Click Supplemental Materials under article title in Contents at

Objective

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 2 million people, caused thousands of deaths, and become a worldwide pandemic. To effectively block its transmission, all possible transmission routes must be determined. SARS-CoV-2 has been identified previously in throat and anal swabs, urine, and tears. However, little has been reported about SARS-CoV-2 in the female genital tract, which may provide direct evidence on sexual and mother-to-child transmission. This study aimed to determine whether SARS-CoV-2 exists in the lower female genital tract (including vaginal fluid and cervical exfoliated cells).

Study Design

In this study, we recruited 35 women with coronavirus disease 2019 (COVID-19) from Jan. 28, 2020, to Feb. 18, 2020, in 3 branches of the Tongji Hospital: Sino-French New City Branch (16 cases), Optical Valley Branch (16 cases), and Hankou Main Campus (3 cases). Patients received a diagnosis of COVID-19 based on the New Coronavirus Pneumonia Prevention and Control Program (5th edition) published by the National Health Commission of China (NHCC). Written informed consent was obtained from each enrolled patient. A total of 27 patients had a positive result for SARS-CoV-2 by reverse transcription polymerase chain reaction (RT-PCR) analysis on samples from the respiratory tract, which were consistent with the interim guidelines of the World Health Organization (WHO). Eight patients received a clinical diagnosis of COVID-19 based on the NHCC guidelines, as mentioned previously. It was a special situation in Wuhan, China, that many patients received a clinical diagnosis of COVID-19 and were admitted to COVID-19–specific hospitals based on the NHCC guidelines. Patients had typical epidemiologic histories, symptoms, and computed tomography scans but lacked throat swabs with positive results. These patients were included to investigate if SARS-CoV-2 could be found in the genital tract considering that it was difficult to detect in the upper respiratory tract. To avoid false-negative results, 3 different types of samples were obtained from each patient, including vaginal fluid, exfoliated cell, and anal swab. Each type of sample was collected twice and tested at 2 separate laboratories. Vaginal fluid samples were obtained from the posterior vagina fornix using a speculum. Swabs were rotated for 5 seconds and extracted while rotating (sampling kit from Yocon, Beijing, China). Exfoliated cell samples were collected from the cervix (or vaginal residue of patients who had undergone hysterectomy) according to the protocol of the ThinPrep cytologic test (Hologic, Marlborough, MA). The anal swab was inserted 3 cm into the anal canal and rotated for 5 seconds (sampling kit from Yocon, Beijing, China). None of the patients were admitted to the intensive care, and none had invasive ventilation; all had the ability to cooperate completely and to assume a lithotomy position, to follow the standard gynecologic examination protocol during sampling. Following the WHO guidelines for real-time RT-PCR, all samples were tested for SARS-CoV-2 using the recommended Chinese Center for Disease Control and Prevention kit (Daan Gene, Guangzhou, China, or BioPerfectus Technologies, Jiangsu, China). All the samples were processed separately and simultaneously at Tongji Hospital, Department of Clinical Laboratory, Wuhan, China, and Wuhan KDWS Biological Technology Co, Ltd, Wuhan, China. Sample collection, processing, and laboratory testing followed WHO guidelines. Positive cases were defined as patients with a positive test result from either laboratory.

Results

The age range of the 35 patients was 37–88 years. Most patients were natives of Wuhan, China. More than 50% of patients had chronic diseases. The interval from the first symptoms of COVID-19 to the time of taking the samples varied between 8 and 41 days. Twenty-eight patients had entered the menopause stage. One patient was postpartum and had just undergone a cesarean delivery. As a consequence, the sampling covered women who were postpartum and postmenopausal and women of reproductive age (Table ).
Table

SARS-CoV-2 test by RT-PCR for vaginal fluid, cervical exfoliated cells, and anal swab samples

Patient no.Age, yMenopauseDays from first symptoms to samplingThroat swabVaginal fluidCervical exfoliated cellsAnal swab
174Yes24+
260Yes27+
359Yes36+
464Yes31+
560Yes21
675Yes23+
788Yes26+
846No26+
956Yes27+
1069Yes26+
1156Yes25+
1255Yes25
1370Yes31+
1448No28+
1537Postpartum28
1671Yes31+
1771Yes41
1856Yes20+
1941No23+
2073Yes22+
2163Yes14
2267Yes21
2351No24
2444No21
2576Yes22+
2663Yes13+
2769Yes9+
2865Yes11+
2944No14+
3064Yes8++
3153Yes15+
3266Yes26+
3367Yes29+
3467Yes26+
3566Yes26+

The “+” symbol stands for positive results, and “−” symbol stands for negative results.

RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Cui. Severe acute respiratory syndrome coronavirus 2 detection in the female lower genital tract. Am J Obstet Gynecol 2020.

SARS-CoV-2 test by RT-PCR for vaginal fluid, cervical exfoliated cells, and anal swab samples The “+” symbol stands for positive results, and “−” symbol stands for negative results. RT-PCR, reverse transcription polymerase chain reaction; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Cui. Severe acute respiratory syndrome coronavirus 2 detection in the female lower genital tract. Am J Obstet Gynecol 2020. Results from all samples of vaginal fluid, cervical exfoliated cells, and anal swab are presented in the Table. One anal swab sample was positive for SARS-CoV-2, which is consistent with previous research, and indicated that the digestive tract was a possible transmission route. All samples from the lower genital tract were negative for SARS-CoV-2. This negative result might be explained by the negative expression of angiotensin-converting enzyme 2, the receptor of SARS-CoV-2, in the vagina and cervix. We obtained breast milk from the 1 postpartum patient on the third day after delivery. A neonatologist helped to obtain neonatal throat swab samples. All the samples were negative for SARS-CoV-2, consistent with a previous study in which no SARS-CoV-2 was found in amniotic fluid, umbilical cord blood, and neonatal throat swabs. The strengths of our study include that both reproductive-age and postmenopausal women were included, multiple sites of the vagina were sampled, and all samples were double tested. Similar results were reported recently in a smaller study (n=10) in which no SARS-CoV-2 was detected in vaginal fluid. Our study was limited largely by sample size. Larger studies including many young patients and the mildly or moderately ill are needed to confirm the results. Furthermore, because samples from sex partners of the patients enrolled were missing, including anal swabs, semen, and urethral orifice swabs, we could not study whether sexual activity is a mode for transmission.

Conclusion

SARS-CoV-2 was not found in vaginal fluid and cervical exfoliated cells. Our results showed that the lower female genital tract may not be a transmission route for SARS-CoV-2. These results may help in the selection of the method of delivery for pregnant women with SARS-CoV-2 infection.
  4 in total

1.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

2.  Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records.

Authors:  Huijun Chen; Juanjuan Guo; Chen Wang; Fan Luo; Xuechen Yu; Wei Zhang; Jiafu Li; Dongchi Zhao; Dan Xu; Qing Gong; Jing Liao; Huixia Yang; Wei Hou; Yuanzhen Zhang
Journal:  Lancet       Date:  2020-02-12       Impact factor: 79.321

3.  Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence.

Authors:  Lisheng Wang; Yiru Wang; Dawei Ye; Qingquan Liu
Journal:  Int J Antimicrob Agents       Date:  2020-03-19       Impact factor: 5.283

4.  SARS-CoV-2 Is Not Detectable in the Vaginal Fluid of Women With Severe COVID-19 Infection.

Authors:  Lin Qiu; Xia Liu; Meng Xiao; Jing Xie; Wei Cao; Zhengyin Liu; Abraham Morse; Yuhua Xie; Taisheng Li; Lan Zhu
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 20.999

  4 in total
  19 in total

Review 1.  Effects of SARS-CoV-2 infection on human reproduction.

Authors:  Ming Yang; Jing Wang; Yidong Chen; Siming Kong; Jie Qiao
Journal:  J Mol Cell Biol       Date:  2021-12-30       Impact factor: 6.216

2.  Vertical transmission of SARS-CoV-2: A prospective cross-sectional study from a tertiary center.

Authors:  Selcan Sinaci; Doga F Ocal; Banu Seven; Ali T Anuk; Berhan Besimoglu; Mehmet C Keven; Sule Goncu Ayhan; Mustafa S Akin; Cuneyt Tayman; Huseyin L Keskin; Elif G Yapar Eyi; Bedia Dinc; Ozlem Moraloglu Tekin; Dilek Sahin
Journal:  J Med Virol       Date:  2021-06-12       Impact factor: 20.693

3.  Detection of COVID-19 in a Vulvar Lesion.

Authors:  Stephanie A Sansone; Elizabeth S Rubin; Adi Hirshberg; Elizabeth G Clement; Sindhu K Srinivas
Journal:  Am J Perinatol       Date:  2020-07-02       Impact factor: 1.862

Review 4.  COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development.

Authors:  Ramandeep Singh; Alisha Kang; Xiangqian Luo; Mangalakumari Jeyanathan; Amy Gillgrass; Sam Afkhami; Zhou Xing
Journal:  FASEB J       Date:  2021-03       Impact factor: 5.834

Review 5.  Towards a sensitive and accurate interpretation of molecular testing for SARS-CoV-2: a rapid review of 264 studies.

Authors:  Kamelia R Stanoeva; Annemiek A van der Eijk; Adam Meijer; Laetitia M Kortbeek; Marion P G Koopmans; Chantal B E M Reusken
Journal:  Euro Surveill       Date:  2021-03

6.  Analysis of Ovarian Injury Associated With COVID-19 Disease in Reproductive-Aged Women in Wuhan, China: An Observational Study.

Authors:  Ting Ding; Tian Wang; Jinjin Zhang; Pengfei Cui; Zhe Chen; Su Zhou; Suzhen Yuan; Wenqing Ma; Minli Zhang; Yueguang Rong; Jiang Chang; Xiaoping Miao; Xiangyi Ma; Shixuan Wang
Journal:  Front Med (Lausanne)       Date:  2021-03-19

Review 7.  Being pregnant in the COVID-19 pandemic: Effects on the placenta in all aspects.

Authors:  C Merve Seymen
Journal:  J Med Virol       Date:  2021-02-15       Impact factor: 20.693

Review 8.  COVID-19 may affect male fertility but is not sexually transmitted: a systematic review.

Authors:  Ilan Tur-Kaspa; Tomer Tur-Kaspa; Grace Hildebrand; David Cohen
Journal:  F S Rev       Date:  2021-02-03

9.  SARS-CoV-2 and human reproduction: An open question.

Authors:  Frida Entezami; Marise Samama; Nathalie Dejucq-Rainsford; Louis Bujan
Journal:  EClinicalMedicine       Date:  2020-07-24

Review 10.  A comprehensive review of the impact of COVID-19 on human reproductive biology, assisted reproduction care and pregnancy: a Canadian perspective.

Authors:  Mitko Madjunkov; Michal Dviri; Clifford Librach
Journal:  J Ovarian Res       Date:  2020-11-27       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.